SCHEMBL112752

SCHEMBL112752

CCOC(=O)C(C)(CC)c1ccc(N)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 3/20 0.37
KCNQ2 O43526 3/20 0.37
KCNQ4 P56696 2/20 0.37
KCNQ5 Q9NR82 2/20 0.37
ESR1 P03372 1/20 0.36
AR P10275 1/20 0.36
ESR2 Q92731 1/20 0.36
TSHR P16473 3/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 2/20 0.35
OPRK1 P41145 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
FBP1 P09467 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ABCB11 O95342 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30853648 0.86 TSHR (0.36) KCNQ3KCNQ2KCNQ4KCNQ5ESR1
SCHEMBL14035562 0.86 CNR2 (0.45) TSHRMAPTKDM4ENPC1RAB9A
SCHEMBL30192734 0.86 CNR2 (0.45) TSHRMAPTKDM4ENPC1RAB9A
SCHEMBL140210 0.86 TSHR (0.36) KCNQ3KCNQ2KCNQ4KCNQ5ESR1
SCHEMBL28015001 0.84 HDAC1 (0.33) ESR1ARESR2HDAC1HDAC6
SCHEMBL11156490 0.81 POLB (0.37) KCNQ3KCNQ2KCNQ4KCNQ5MAPT
SCHEMBL140211 0.81 POLB (0.49) KCNQ3KCNQ2KCNQ4KCNQ5ESR1
SCHEMBL112748 0.79 THRB (0.45) MAPTKDM4ESMN1; SMN2FBP1ALDH1A1
SCHEMBL8432943 0.76 CNR2 (0.44) TSHRMAPTOPRK1NPC1RAB9A
SCHEMBL1712071 0.75 PPARA (0.57) TSHROPRK1FBP1ABCB11CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK KCNQ3 2680/4885KCNQ2 2179/4885KCNQ4 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.